MX2011004245A - Composicion para dirigirse a las celulas dendriticas. - Google Patents

Composicion para dirigirse a las celulas dendriticas.

Info

Publication number
MX2011004245A
MX2011004245A MX2011004245A MX2011004245A MX2011004245A MX 2011004245 A MX2011004245 A MX 2011004245A MX 2011004245 A MX2011004245 A MX 2011004245A MX 2011004245 A MX2011004245 A MX 2011004245A MX 2011004245 A MX2011004245 A MX 2011004245A
Authority
MX
Mexico
Prior art keywords
composition
dendritic cells
targeting dendritic
relates
present
Prior art date
Application number
MX2011004245A
Other languages
English (en)
Inventor
Rudolf Maria De Wildt
Joseph Altin
Ines Atmosukarto
Christopher Parish
Jason Price
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of MX2011004245A publication Critical patent/MX2011004245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

La presente invención se refiere a una composición para dirigirse a las células dendríticas. En particular, la presente invención se refiere a una composición que comprende: a) uno o más antígenos; b) un solo dominio variable de inmunoglobulina anti-DC-SIGN; y c) un vehículo que es portador de a) y b). La invención se refiere además a formulaciones, composiciones, y dispositivos que comprenden estas moléculas anti-DC-SIGN, y su uso como un medicamento, y en el tratamiento de cáncer, adecuadamente melanoma.
MX2011004245A 2008-10-21 2009-10-19 Composicion para dirigirse a las celulas dendriticas. MX2011004245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10709508P 2008-10-21 2008-10-21
PCT/EP2009/063656 WO2010046338A1 (en) 2008-10-21 2009-10-19 Composition for targeting dendritic cells

Publications (1)

Publication Number Publication Date
MX2011004245A true MX2011004245A (es) 2011-09-06

Family

ID=41600775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011004245A MX2011004245A (es) 2008-10-21 2009-10-19 Composicion para dirigirse a las celulas dendriticas.

Country Status (18)

Country Link
US (2) US8779107B2 (es)
EP (1) EP2355797A1 (es)
JP (1) JP2012506371A (es)
KR (1) KR20110101134A (es)
CN (1) CN102281867A (es)
AU (1) AU2009306425B2 (es)
BR (1) BRPI0919670A2 (es)
CA (1) CA2740857A1 (es)
CL (1) CL2011000911A1 (es)
CO (1) CO6361908A2 (es)
EA (1) EA201100485A1 (es)
IL (1) IL212147A0 (es)
MA (1) MA32815B1 (es)
MX (1) MX2011004245A (es)
NZ (1) NZ592084A (es)
PE (1) PE20110775A1 (es)
WO (1) WO2010046338A1 (es)
ZA (1) ZA201102764B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120132183A (ko) * 2011-05-27 2012-12-05 포항공과대학교 산학협력단 종양 조직에서 유래한 나노소포체 및 이를 이용한 암 백신
EP3873532A1 (en) 2018-10-31 2021-09-08 Novartis AG Dc-sign antibody drug conjugates
US20220233607A1 (en) * 2019-05-29 2022-07-28 Université De Tours Toxoplasma platform for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1639011E (pt) * 2003-06-30 2009-01-20 Domantis Ltd Anticorpos (dab) de domínio único peguilados
CN1893925B (zh) * 2003-08-21 2011-04-27 利普泰克有限公司 树突细胞的体内靶向
CN102257009A (zh) * 2008-10-21 2011-11-23 杜门蒂斯有限公司 具有针对dc-sign的结合特异性的配体

Also Published As

Publication number Publication date
US20140341971A1 (en) 2014-11-20
KR20110101134A (ko) 2011-09-15
CO6361908A2 (es) 2012-01-20
US8779107B2 (en) 2014-07-15
AU2009306425A1 (en) 2010-04-29
ZA201102764B (en) 2012-09-26
CA2740857A1 (en) 2010-04-29
BRPI0919670A2 (pt) 2019-09-24
CN102281867A (zh) 2011-12-14
EP2355797A1 (en) 2011-08-17
NZ592084A (en) 2013-01-25
PE20110775A1 (es) 2011-10-21
WO2010046338A1 (en) 2010-04-29
AU2009306425B2 (en) 2013-09-12
EA201100485A1 (ru) 2011-12-30
IL212147A0 (en) 2011-06-30
CL2011000911A1 (es) 2012-02-03
MA32815B1 (fr) 2011-11-01
US20110212168A1 (en) 2011-09-01
JP2012506371A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX2015000821A (es) Compuestos para inmunoterapia dirigida.
MX370721B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
EP2321264A4 (en) DEACETYLASEINHIBITORS AND APPLICATIONS THEREOF
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12014501229A1 (en) Antibody-drug conjugates and related compounds, compositions, and methods
MY162146A (en) Pharmaceutical composition
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BR112014015909A2 (pt) composição
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
WO2011082273A3 (en) Substituted pyrrolo-aminopyrimidine compounds
MX339862B (es) Compuestos imidazopiridinil-aminopiridina substituidos.
MX2012000396A (es) Metodos y composiciones para uso en tartamientos celulares.
MX2013002417A (es) Composiciones pesticidas.
WO2011082267A8 (en) Substituted triazolo-pyrazine compounds
MX2011003738A (es) Conjugados hpma-docetaxel o gemcitabine y sus usos asociados.
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
UA98804C2 (ru) Катехоламиновые производные и фармацевтическая композиция на их основе
DK2252322T3 (da) Vaccinesammensætninger
WO2011123678A3 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
WO2011082268A3 (en) Substituted naphthalenyl-pyrimidine compounds
MX2011004245A (es) Composicion para dirigirse a las celulas dendriticas.
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
WO2012061342A3 (en) Substituted benzo-imidazo-pyrido-diazepine compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal